Precision Oncology Companies, Business & Management Outlook
The global precision oncology market is projected to grow from USD 120.9 billion in 2024 to USD 310.75 billion by 2034, representing a robust compound annual growth rate (CAGR) of 9.9% over the period from 2024 to 2034.
Top Companies in the Precision Oncology Market
- AbbVie
- ACT Oncology
- AstraZeneca
- Bristol Myers Squibb
- Gilead Sciences
- Illumina, Inc.
- Insilico Medicine
- Johnson & Johnson
- Maze Therapeutics, Inc.
- Myriad Genetics
- Novartis
- Pfizer
- Qiagen N.V.
- Roche Diagnostics
Recent Developments in the Precision Oncology Market
- In October 2024, the National Institute of Health launched the myeloMATCH precision medicine clinical trial to test new treatment combinations targeting specific genetic changes in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) cancer cells.
- In April 2024, LabCorp announced the expansion of its precision oncology portfolio to advance cancer research and patient care on a global scale. It launched a novel platform for molecular residual disease (MRD), Labcorp Plasma Detect, for ctDNA genomic profiling solution.
Consignment and Shipper Details of Pharma Products in the U.S.
| CONSIGNEE NAME |
SHIPPER NAME |
PRODUCT DESCRIPTION |
QUANTITY |
WEIGHT |
| STRIDES PHARMA INC |
STRIDES PHARMA GLOBAL PTELIMITED |
PHARMACEUTICAL PRODUCTS |
1577 |
10544 |
| NORTHSTAR DISTRIBUTION CENTER 8912 |
AVET LIFESCIENCES PRIVATE LIMITED |
PHARMA HTS: 300490 |
17 |
5715 |
| BOEKEL SCIENTIFIC |
FOUR E S SCIENTIFIC HONGKONG LIMITED |
LAB-JACKS |
218 |
3932 |
| HOSPIRA WORLDWIDE INC |
PFIZER HEALTHCARE INDIA PRIVATE LIMITED |
PHARMACEUTICALS LIDOCAINE HCL |
34 |
12931 |
| UPS SUPPLY CHAIN SOLUTIONS |
LUPIN LIMITED |
DULOXETINE DR CAP 30MG 30S USP 1013 CARTONS |
40 |
12823 |
